Cargando…

Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment

BACKGROUND: Phosphomannomutase deficiency (PMM2-CDG) is the most frequent congenital disorder of glycosylation. The cerebellum is nearly always affected in PMM2-CDG patients, a cerebellar atrophy progression is observed, and cerebellar dysfunction is their main daily functional limitation. Different...

Descripción completa

Detalles Bibliográficos
Autores principales: Serrano, Mercedes, de Diego, Víctor, Muchart, Jordi, Cuadras, Daniel, Felipe, Ana, Macaya, Alfons, Velázquez, Ramón, Poo, M. Pilar, Fons, Carmen, O’Callaghan, M. Mar, García-Cazorla, Angels, Boix, Cristina, Robles, Bernabé, Carratalá, Francisco, Girós, Marisa, Briones, Paz, Gort, Laura, Artuch, Rafael, Pérez-Cerdá, Celia, Jaeken, Jaak, Pérez, Belén, Pérez-Dueñas, Belén
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623922/
https://www.ncbi.nlm.nih.gov/pubmed/26502900
http://dx.doi.org/10.1186/s13023-015-0358-y
_version_ 1782397762561638400
author Serrano, Mercedes
de Diego, Víctor
Muchart, Jordi
Cuadras, Daniel
Felipe, Ana
Macaya, Alfons
Velázquez, Ramón
Poo, M. Pilar
Fons, Carmen
O’Callaghan, M. Mar
García-Cazorla, Angels
Boix, Cristina
Robles, Bernabé
Carratalá, Francisco
Girós, Marisa
Briones, Paz
Gort, Laura
Artuch, Rafael
Pérez-Cerdá, Celia
Jaeken, Jaak
Pérez, Belén
Pérez-Dueñas, Belén
author_facet Serrano, Mercedes
de Diego, Víctor
Muchart, Jordi
Cuadras, Daniel
Felipe, Ana
Macaya, Alfons
Velázquez, Ramón
Poo, M. Pilar
Fons, Carmen
O’Callaghan, M. Mar
García-Cazorla, Angels
Boix, Cristina
Robles, Bernabé
Carratalá, Francisco
Girós, Marisa
Briones, Paz
Gort, Laura
Artuch, Rafael
Pérez-Cerdá, Celia
Jaeken, Jaak
Pérez, Belén
Pérez-Dueñas, Belén
author_sort Serrano, Mercedes
collection PubMed
description BACKGROUND: Phosphomannomutase deficiency (PMM2-CDG) is the most frequent congenital disorder of glycosylation. The cerebellum is nearly always affected in PMM2-CDG patients, a cerebellar atrophy progression is observed, and cerebellar dysfunction is their main daily functional limitation. Different therapeutic agents are under development, and clinical evaluation of drug candidates will require a standardized score of cerebellar dysfunction. We aim to assess the validity of the International Cooperative Ataxia Rating Scale (ICARS) in children and adolescents with genetically confirmed PMM2-CDG deficiency. We compare ICARS results with the Nijmegen Pediatric CDG Rating Scale (NPCRS), neuroimaging, intelligence quotient (IQ) and molecular data. METHODS: Our observational study included 13 PMM2-CDG patients and 21 control subjects. Ethical permissions and informed consents were obtained. Three independent child neurologists rated PMM2-CDG patients and control subjects using the ICARS. A single clinician administered the NPCRS. All patients underwent brain MRI, and the relative diameter of the midsagittal vermis was measured. Psychometric evaluations were available in six patients. The Mann–Whitney U test was used to compare ICARS between patients and controls. To evaluate inter-observer agreement in patients’ ICARS ratings, intraclass correlation coefficients (ICC) were calculated. ICARS internal consistency was evaluated using Cronbach’s alpha. Spearman’s rank correlation coefficient test was used to correlate ICARS with NPCRS, midsagittal vermis relative diameter and IQ. RESULTS: ICARS and ICARS subscores differed between patients and controls (p < 0.001). Interobserver agreement of ICARS was “almost perfect” (ICC = 0.99), with a “good” internal reliability (Cronbach’s alpha = 0.72). ICARS was significantly correlated with the total NPCRS score (r(s) 0.90, p < 0.001). However, there was no agreement regarding categories of severity. Regarding neuroimaging, inverse correlations between ICARS and midsagittal vermis relative diameter (r(s) −0.85, p = 0.003) and IQ (r(s) −0.94, p = 0.005) were found. Patients bearing p.E93A, p.C241S or p.R162W mutations presented a milder phenotype. CONCLUSIONS: ICARS is a reliable instrument for assessment of PMM2-CDG patients, without significant inter-rater variability. Despite our limited sample size, the results show a good correlation between functional cerebellar assessment, IQ and neuroimagingFor the first a correlation between ICARS, neuroimaging and IQ in PMM2-CDG patients has been demonstrated.
format Online
Article
Text
id pubmed-4623922
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46239222015-10-29 Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment Serrano, Mercedes de Diego, Víctor Muchart, Jordi Cuadras, Daniel Felipe, Ana Macaya, Alfons Velázquez, Ramón Poo, M. Pilar Fons, Carmen O’Callaghan, M. Mar García-Cazorla, Angels Boix, Cristina Robles, Bernabé Carratalá, Francisco Girós, Marisa Briones, Paz Gort, Laura Artuch, Rafael Pérez-Cerdá, Celia Jaeken, Jaak Pérez, Belén Pérez-Dueñas, Belén Orphanet J Rare Dis Research BACKGROUND: Phosphomannomutase deficiency (PMM2-CDG) is the most frequent congenital disorder of glycosylation. The cerebellum is nearly always affected in PMM2-CDG patients, a cerebellar atrophy progression is observed, and cerebellar dysfunction is their main daily functional limitation. Different therapeutic agents are under development, and clinical evaluation of drug candidates will require a standardized score of cerebellar dysfunction. We aim to assess the validity of the International Cooperative Ataxia Rating Scale (ICARS) in children and adolescents with genetically confirmed PMM2-CDG deficiency. We compare ICARS results with the Nijmegen Pediatric CDG Rating Scale (NPCRS), neuroimaging, intelligence quotient (IQ) and molecular data. METHODS: Our observational study included 13 PMM2-CDG patients and 21 control subjects. Ethical permissions and informed consents were obtained. Three independent child neurologists rated PMM2-CDG patients and control subjects using the ICARS. A single clinician administered the NPCRS. All patients underwent brain MRI, and the relative diameter of the midsagittal vermis was measured. Psychometric evaluations were available in six patients. The Mann–Whitney U test was used to compare ICARS between patients and controls. To evaluate inter-observer agreement in patients’ ICARS ratings, intraclass correlation coefficients (ICC) were calculated. ICARS internal consistency was evaluated using Cronbach’s alpha. Spearman’s rank correlation coefficient test was used to correlate ICARS with NPCRS, midsagittal vermis relative diameter and IQ. RESULTS: ICARS and ICARS subscores differed between patients and controls (p < 0.001). Interobserver agreement of ICARS was “almost perfect” (ICC = 0.99), with a “good” internal reliability (Cronbach’s alpha = 0.72). ICARS was significantly correlated with the total NPCRS score (r(s) 0.90, p < 0.001). However, there was no agreement regarding categories of severity. Regarding neuroimaging, inverse correlations between ICARS and midsagittal vermis relative diameter (r(s) −0.85, p = 0.003) and IQ (r(s) −0.94, p = 0.005) were found. Patients bearing p.E93A, p.C241S or p.R162W mutations presented a milder phenotype. CONCLUSIONS: ICARS is a reliable instrument for assessment of PMM2-CDG patients, without significant inter-rater variability. Despite our limited sample size, the results show a good correlation between functional cerebellar assessment, IQ and neuroimagingFor the first a correlation between ICARS, neuroimaging and IQ in PMM2-CDG patients has been demonstrated. BioMed Central 2015-10-26 /pmc/articles/PMC4623922/ /pubmed/26502900 http://dx.doi.org/10.1186/s13023-015-0358-y Text en © Serrano et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Serrano, Mercedes
de Diego, Víctor
Muchart, Jordi
Cuadras, Daniel
Felipe, Ana
Macaya, Alfons
Velázquez, Ramón
Poo, M. Pilar
Fons, Carmen
O’Callaghan, M. Mar
García-Cazorla, Angels
Boix, Cristina
Robles, Bernabé
Carratalá, Francisco
Girós, Marisa
Briones, Paz
Gort, Laura
Artuch, Rafael
Pérez-Cerdá, Celia
Jaeken, Jaak
Pérez, Belén
Pérez-Dueñas, Belén
Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment
title Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment
title_full Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment
title_fullStr Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment
title_full_unstemmed Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment
title_short Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment
title_sort phosphomannomutase deficiency (pmm2-cdg): ataxia and cerebellar assessment
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623922/
https://www.ncbi.nlm.nih.gov/pubmed/26502900
http://dx.doi.org/10.1186/s13023-015-0358-y
work_keys_str_mv AT serranomercedes phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment
AT dediegovictor phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment
AT muchartjordi phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment
AT cuadrasdaniel phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment
AT felipeana phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment
AT macayaalfons phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment
AT velazquezramon phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment
AT poompilar phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment
AT fonscarmen phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment
AT ocallaghanmmar phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment
AT garciacazorlaangels phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment
AT boixcristina phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment
AT roblesbernabe phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment
AT carratalafrancisco phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment
AT girosmarisa phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment
AT brionespaz phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment
AT gortlaura phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment
AT artuchrafael phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment
AT perezcerdacelia phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment
AT jaekenjaak phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment
AT perezbelen phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment
AT perezduenasbelen phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment